Evidence map›Paper›PMID 37936683›Full record

ArticleFrontiers in immunology2023

The immune cell landscape of glioblastoma patients highlights a myeloid-enriched and immune suppressed microenvironment compared to metastatic brain tumors.

Beatrice Musca, Maria Giovanna Russo, Ada Tushe, Sara Magri, Greta Battaggia, Laura Pinton, Camilla Bonaudo, Alessandro Della Puppa, Susanna Mandruzzato

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed, 1 pooled it
5.5field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Beatrice MuscaImmunology and Molecular Oncology, Veneto Institute of Oncology IOV - IRCCS, Padova, Italy.
Maria Giovanna RussoImmunology and Molecular Oncology, Veneto Institute of Oncology IOV - IRCCS, Padova, Italy.
Ada TusheDepartment of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy.
Sara MagriDepartment of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy.
Greta BattaggiaImmunology and Molecular Oncology, Veneto Institute of Oncology IOV - IRCCS, Padova, Italy.
Laura PintonImmunology and Molecular Oncology, Veneto Institute of Oncology IOV - IRCCS, Padova, Italy.
Camilla BonaudoNeurosurgery, Department of NEUROFARBA, University Hospital of Careggi, University of Florence, Florence, Italy.
Alessandro Della PuppaNeurosurgery, Department of NEUROFARBA, University Hospital of Careggi, University of Florence, Florence, Italy.
Susanna MandruzzatoImmunology and Molecular Oncology, Veneto Institute of Oncology IOV - IRCCS, Padova, Italy.
Istituti di Ricovero e Cura a Carattere Scientifico · ITUniversity of Florence · ITUniversity of Padua · ITIstituto Oncologico Veneto · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Brain metastases (BrM), which commonly arise in patients with melanoma, breast cancer and lung cancer, are associated with a poor clinical prognosis. In this context, the tumor microenvironment (TME) plays an important role since it either promotes or inhibits tumor progression. Our previous studies have characterized the immunosuppressive microenvironment of glioblastoma (GBM). The aim of this study is to compare the immune profiles of BrM and GBM in order to identify potential differences that may be exploited in their differential treatment. Methods: Tumor and/or blood samples were taken from 20 BrM patients and 19 GBM patients. Multi-parametric flow cytometry was used to evaluate myeloid and lymphoid cells, as well as the expression of immune checkpoints in the TME and blood. In selected cases, the immunosuppressive ability of sorted myeloid cells was tested, and the Results: High frequencies of myeloid cells dominated both the BrM and GBM landscapes, but a higher presence of tumor-associated macrophages was observed in GBM, while BrM were characterized by a significant presence of tumor-infiltrating lymphocytes. Exhaustion markers were highly expressed in all T cells from both primary and metastatic brain tumors. Discussion: Our results define the main characteristics of the immune profile of BrM and GBM, which are distinguished by different levels of immunosuppressive myeloid cells and lymphocytes devoid of effector function. Understanding the role of the different cells in establishing the metastatic setting is critical for improving the therapeutic efficacy of new targeted immunotherapy strategies.

Indexed as

Brain NeoplasmsGlioblastomaHumansLymphocytesMacrophagesT-LymphocytesTumor Microenvironmentbrain metastasesglioblastomamyeloid cellstumor-associated macrophagestumor microenvironment

Identifiers

PMID37936683
PMCPMC10626453
OpenAlexW4387878124

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.